Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | See Remarks | August 04, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date August 04, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 589,355 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 38,800 · Balance 589,355 F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person. F2: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.
F2: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 51,519 | $2.73 | $140,646.87 |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 29,199 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-055368 · doc4.xml · derivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,801 Underlying: Common Stock · 29,199 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · price: Not applicable. F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 29,199 | $50.25 | $1,467,211.79 |
DisclosureSEC source: 0001209191-20-055368 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,518 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.8250 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 29,199 | $2.73 | $79,713.27 |
DisclosureSEC source: 0001209191-20-055368 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-053043 · doc4.xml · derivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 35,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F6 · price: Not applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 6,983 | $41.95 | $292,929.17 |
DisclosureSEC source: 0001209191-20-053043 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,518 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $41.66 to $42.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 6,260 | $41.09 | $257,234.04 |
DisclosureSEC source: 0001209191-20-053043 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,501 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $40.65 to $41.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 21,757 | $40.26 | $875,902.01 |
DisclosureSEC source: 0001209191-20-053043 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,761 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $39.65 to $40.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 35,000 | $2.73 | $95,550.00 |
DisclosureSEC source: 0001209191-20-053043 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $21.99 | Not disclosed |
DisclosureSEC source: 0001209191-20-003026 · doc4.xml · derivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-01-08 F5 · price: Not applicable. F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2020 such that this option is fully exercisable on January 1, 2024. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5,700 | $20.72 | $118,085.19 |
DisclosureSEC source: 0001209191-20-003026 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,518 F2 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election on November 18, 2019 by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.4950 to $20.88 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003026 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,218 F1 · security: Award of restricted stock units ("RSUs") that vests with respect to 1/4 of the underlying shares on each of January 8, 2021, January 8, 2022, January 8, 2023, and January 8, 2024. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 10,200 | $14.24 | $145,291.86 |
DisclosureSEC source: 0001209191-19-053275 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,218 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 20,000 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election on December 18, 2018 by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.94 to $14.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: All remaining shares of Common Stock held by the reporting person are subject to the terms of a lock-up agreement with Jefferies LLC and Citigroup Global Markets Inc. (the "Representatives"), as representatives of the underwriters in the Company's public offering pursuant to a prospectus supplement dated September 11, 2019, pursuant to which the reporting person agreed, without the prior written consent of the Representatives, and subject to limited exceptions, not to sell, offer to sell, contract to sell or lend, effect any short sale, pledge, hypothecate or grant any security interest in, or otherwise transfer or dispose of, any shares of Common Stock, either directly or indirectly. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 14:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-19-016098 · doc4.xml · derivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,149 Underlying: Common Stock · 25,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 14:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,000 | $16.15 | $403,697.50 |
DisclosureSEC source: 0001209191-19-016098 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,418 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 14:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $2.90 | $72,500.00 |
DisclosureSEC source: 0001209191-19-016098 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-19-014022 · doc4.xml · derivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,149 Underlying: Common Stock · 25,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,000 | $16.07 | $401,820.00 |
DisclosureSEC source: 0001209191-19-014022 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,418 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $2.90 | $72,500.00 |
DisclosureSEC source: 0001209191-19-014022 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 135,000 | Not disclosed Strike: $16.55 | Not disclosed |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · derivative · entry 11 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2029-01-06 F4 · price: Not applicable. F6 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2019 such that this option is fully exercisable on January 1, 2023. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 12,451 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · derivative · entry 10 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,149 Underlying: Common Stock · 12,451 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F4 · price: Not applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 8,461 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · derivative · entry 9 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,461 shares Expires 2021-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F4 · price: Not applicable. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 2,080 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · derivative · entry 8 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,080 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F4 · price: Not applicable. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 2,008 | Not disclosed Strike: $1.37 | Not disclosed |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · derivative · entry 7 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,008 shares Expires 2023-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F4 · price: Not applicable. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · nonDerivative · entry 6 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,418 F2 · security: Award of Restricted Stock Units that vests with respect to 1/3 of the underlying shares on each of January 7, 2020, January 7, 2021, and January 7, 2022. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,000 | $16.00 | $400,000.00 |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · nonDerivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,418 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 12,451 | $2.90 | $36,107.90 |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 8,461 | $1.69 | $14,299.09 |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 2,080 | $1.69 | $3,515.20 |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 2,008 | $1.37 | $2,750.96 |
DisclosureSEC source: 0001209191-19-003020 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 200,160 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001209191-18-003923 · doc4.xml · derivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,160 Underlying: Common Stock · 200,160 shares Expires 2028-01-15 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 500 | $4.10 | $2,050.00 |
DisclosureSEC source: 0001209191-17-057148 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,418 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 20,000 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.99 to $4.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes previously reported shares of Common Stock underlying RSUs granted to the reporting person, which are subject to certain vesting conditions. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 7,591 | $3.83 | $29,073.53 |
DisclosureSEC source: 0001209191-17-057148 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,918 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 20,000 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.08 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes previously reported shares of Common Stock underlying RSUs granted to the reporting person, which are subject to certain vesting conditions. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-17-002632 · doc4.xml · derivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.